Top

Journal of Cardiovascular Translational Research

Published in:

01-06-2009

Implantable Device Therapy for the Treatment of Resistant Hypertension

Authors: Nikhil Joshi, Jeremy Taylor, John D. Bisognano

Published in: Journal of Cardiovascular Translational Research | Issue 2/2009

Abstract

The prevalence of resistant hypertension continues to increase and the standard approaches of therapeutic lifestyle changes and drug therapy are ineffective in bringing many of these patients to goal blood pressure. Electrical stimulation of the carotid sinus baroreceptor through a surgically implanted device is presently under clinical investigation and is showing some encouraging early results. This review discusses the evolution of this therapy including a review of the current data available from the early stages of ongoing clinical trials.

Rosamond, W., Flegal, K., Furie, K., et al. (2008). Heart disease and stroke statistics 2008 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation, 117, e76–e80.CrossRef

Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., et al. (2007). Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. New England Journal of Medicine, 356, 2388–2398.PubMedCrossRef

Alderman, M. H., Budner, N., Cohen, H., et al. (1988). Prevalence of drug resistant hypertension. Hypertension, 11(Suppl II), II–71–II-75.

Chapleau, M. W. (2008). Arterial baroreflexes. Hypertension primer: the essentials of high blood pressure (4th ed.). London: Lippincott Williams & Wilkins.

Neistadt, A., & Schwartz, S. (1967). Effects of electrical stimulation of the carotid sinus nerve in reversal of experimentally induced hypertension. Surgery, 61, 923–931.PubMed

Lohmeier, T. E. (2001). The sympathetic nervous system and long-term blood pressure regulation. American Journal of Hypertension, 14, 147S–154S.PubMedCrossRef

Bristow, J. D., Honour, A. J., Pickering, G. W., Sleight, P., & Smyth, H. S. (1969). Diminished baroreflex sensitivity in high blood pressure. Circulation, 39, 48–54.PubMed

Matton, G.Carotid sinus and neurogenic and renal hypertension. Journal of Physiology, 129, 13–4P (Abstract).

McCubbin, J. W., Green, J. H., & Page, I. H. (1956). Baroreceptor function in chronic renal hypertension. Circulation Research, 4, 205–210.PubMed

10.

Warner, H. R. (1958). The frequency-dependent nature of blood pressure regulation by the carotid sinus studied with an electrical analog. Circulation Research, 6, 35–40.PubMed

11.

Carlsten, A., Folkow, B., Grimby, G., et al. (1958). Cardiovascular effects of direct stimulation of the carotid sinus nerve in man. Acta Physiologica Scandinavica, 44, 138–145.PubMedCrossRef

12.

Lohmeier, T., Irwin, E., Rossing, M., Serdar, D. J., & Kieval, R. S. (2004). Prolonged activation of the baroreflex produces sustained hypotension. Hypertension, 43, 306–311.PubMedCrossRef

13.

Lohmeier, T. E., Dwyer, T. M., Hildebrandt, D. A., Irwin, E. D., Rossing, M. A., Serdar, D. J., et al. (2005). Influence of prolonged baroreflex activation on arterial pressure in angiotenisn hypertension. Hypertension, 46, 1194–1200.PubMedCrossRef

14.

Lohmeier, T. E., Lohmeier, J. R., Haque, A., & Hildebrandt, D. A. (2000). Baroreflexes prevent neurally induced sodium retention in angiotensin hypertension. American of Journal of Physiology Regulatory Integrative and Comparative Physiology, 279, R1437–R1448.

15.

Xu, L., & Sved, A. F. (2002). Acute sympathoexcitatory action of angiotensin II in conscious baroreceptor-denervated rats. American Journal of Regulatory, Integrative, and Comparative Physiology, 283, R451–R459.

16.

Lohmeier, T. E., Hildebrandt, D. A., Dwyer, T. M., et al. (2007). Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension, 49, 373–379.PubMedCrossRef

17.

Bilgutay, A., & Lillehei, W. (1965). Treatment of hypertension with an implantable electronic device. Journal of the American Medical Association, 191, 113–117.

18.

Bilgutay, A., & Lillehei, W. (1966). Surgical treatment of baropacing with reference to baropacing. American Journal of Cardiology, 17, 663–667.PubMedCrossRef

19.

Schwartz, S., Griffith, L., Neistadt, A., & Hagfors, N. (1967). Chronic carotid sinus nerve stimulation in the treatment of essential hypertension. American Journal of Surgical, 114, 5–15.CrossRef

20.

Tuckman, J., Reichman, T., Lyon, A., et al. (1967). Electrical stimulation of the sinus nerves in hypertensive patients: clinical evaluation and physiological studies. Hypertension, 194S, 23–28.

21.

Lohmeier, T. E., Barrett, A. M., & Irwin, E. D. (2005). Prolonged activation of the baroreflex: a viable approach for the treatment of hypertension? Current Hypertension Reports, 7, 193–198.PubMedCrossRef

22.

Illig, K. A., Levy, M., Sanchez, L., et al. (2006). An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. Journal of Vascular Surgery, 44, 1213–1218.PubMedCrossRef

23.

Bisognano, J., Sloand, J., Papademetriou, V., et al. (2006). An implantable carotid sinus baroreflex activating system for drug-resistant hypertension: interim chronic efficacy results from the multi-center Rheos Feasibility Trial. Circulation, 114, II_575 (Abstract 2751).

24.

Scheffers, I., Schmidli, J., Kroon, A. A., et al. (2008). Sustained blood pressure reduction by baroreflex hypertension therapy with a chronically implanted system: 2-year data from the Rheos DEBuT-HT study in patients with resistant hypertension. Journal of Hypertension, 26(Suppl 1), S19.

25.

De Leeuw, P., Gangahar, D., Bach, D., & Lovett, E. (2008). Left ventricular reverse remodeling with chronic treatment of resistant hypertension using an implantable device: results from European and United States Trials of the Rheos Baroreflex Hypertension Therapy System. Journal of Hypertension, 26(Suppl 1), S471.

26.

Scheffers, I., Kroon, A., & De Leeuw, P. (2008). Renal hemodynamics during chronic therapy with electrical stimulation of the carotid sinus in humans. Journal of Hypertension, 26(Suppl 1), S465.

27.

Sabbah, H. N., Imai, M., Irwin, E., et al. (2005). Chronic electrical activation of the carotid baroreflex improves left ventricular systolic and diastolic function in dogs with advanced heart failure. Circulation, 112(17 II), 557.

Title: Implantable Device Therapy for the Treatment of Resistant Hypertension
Authors: Nikhil Joshi
Jeremy Taylor
John D. Bisognano
Publication date: 01-06-2009
Publisher: Springer US
Published in: Journal of Cardiovascular Translational Research / Issue 2/2009
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-009-9093-x

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Implantable Device Therapy for the Treatment of Resistant Hypertension

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Impella 2.5

A Gene Expression Profile of the Myocardial Response to Clenbuterol

Bone-Marrow-Derived Side Population Cells for Myocardial Regeneration

Bone Marrow Stem Cells for the Treatment of Ischemic Heart Disease: A Clinical Trial Review

Chronic Treatment with Clenbuterol Modulates Endothelial Progenitor Cells and Circulating Factors in a Murine Model of Cardiomyopathy

Pediatric Cardiac Devices—An FDA Pediatrician’s Perspective of the Challenges and Potential Solutions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page